Strausz, J., Csoma, Zs., Kovács, G., et al.: Korányi Bulletin. [Korányi Bulletin.], 2011, 1, 16. [Hungarian]

Kovács G. , 'Korányi Bulletin ' (2011 ) 1 Korányi Bulletin : 16 -.

Kovács G.Korányi BulletinKorányi Bulletin2011116)| false
• Search Google Scholar

Zheng, Z., Chen, T., Li, X., et al.: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med., 2007, 356, 800–808.

Li X. , 'DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer ' (2007 ) 356 N. Engl. J. Med. : 800 -808.

Li X.DNA synthesis and repair genes RRM1 and ERCC1 in lung cancerN. Engl. J. Med.2007356800808)| false
• Search Google Scholar

Martin, L. P., Hamilton, T. C., Schilder, R. J.: Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res., 2008, 14, 1291–1295.

Schilder R. J. , 'Platinum resistance: the role of DNA repair pathways ' (2008 ) 14 Clin. Cancer Res. : 1291 -1295.

Schilder R. J.Platinum resistance: the role of DNA repair pathwaysClin. Cancer Res.20081412911295)| false
• Search Google Scholar

Okuda, K., Sasaki, H., Dumontet, C., et al.: Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer, 2008, 62, 105–112.

Dumontet C. , 'Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer ' (2008 ) 62 Lung Cancer : 105 -112.

Dumontet C.Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancerLung Cancer200862105112)| false
• Search Google Scholar

Sun, J. M., Han, J., Ahn, J. S., et al.: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J. Thorac. Oncol., 2011, 6, 1392–1399.

Ahn J. S. , 'Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy ' (2011 ) 6 J. Thorac. Oncol. : 1392 -1399.

Ahn J. S.Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapyJ. Thorac. Oncol.2011613921399)| false
• Search Google Scholar

Bepler, G., Sommers, K. E., Cantor, A., et al.: Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J. Thorac. Oncol., 2008, 3, 1112–1118.

Cantor A. , 'Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer ' (2008 ) 3 J. Thorac. Oncol. : 1112 -1118.

Cantor A.Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancerJ. Thorac. Oncol.2008311121118)| false
• Search Google Scholar

Avien-Ronen, S., Blackhall, F. H., Shepherd, F. A., et al.: K-ras mutations in non-small-cell lung carcinoma: a review. Clin. Lung Cancer, 2006, 8, 30–38.

Shepherd F. A. , 'K-ras mutations in non-small-cell lung carcinoma: a review ' (2006 ) 8 Clin. Lung Cancer : 30 -38.

Shepherd F. A.K-ras mutations in non-small-cell lung carcinoma: a reviewClin. Lung Cancer200683038)| false
• Search Google Scholar

Yoshimasu, T., Oura, S., Ohta, F., et al.: Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer. J. Thorac. Oncol., 2011, 6, 1658–1662.

Ohta F. , 'Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer ' (2011 ) 6 J. Thorac. Oncol. : 1658 -1662.

Ohta F.Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancerJ. Thorac. Oncol.2011616581662)| false
• Search Google Scholar

Camidge, D. R., Kono, S. A., Lu, X., et al.: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol., 2011, 6, 774–780.

Lu X. , 'Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed ' (2011 ) 6 J. Thorac. Oncol. : 774 -780.

Lu X.Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedJ. Thorac. Oncol.20116774780)| false
• Search Google Scholar

Simon, G. R., Schell, M. J., Begum, M., et al.: Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancer, 2011, 112, 2021–2029.

Begum M. , 'Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis ' (2011 ) 112 Cancer : 2021 -2029.

Begum M.Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysisCancer201111220212029)| false
• Search Google Scholar

Vilmar, A., Garcia-Foncillas, J., Huarriz, M., et al.: RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer, 2012, 75, 306–312. [Available online 13 October 2011]

Huarriz M. , 'RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC ' (2012 ) 75 Lung Cancer : 306 -312.

Huarriz M.RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLCLung Cancer201275306312)| false
• Search Google Scholar

Sandler, A., Gray, R., Perry, M. C., et al.: Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell ling cancer. N. Engl. J. Med., 2006, 355, 2542–2550.

Perry M. C. , 'Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell ling cancer ' (2006 ) 355 N. Engl. J. Med. : 2542 -2550.

Perry M. C.Paclitaxel-carboplatin alone or with bevacuzimab for non-small-cell ling cancerN. Engl. J. Med.200635525422550)| false
• Search Google Scholar

Pirker, R., Pereira, J. R., Szczesna, A., et al.: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373, 1525–1531.

Szczesna A. , 'Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial ' (2009 ) 373 Lancet : 1525 -1531.

Szczesna A.Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet200937315251531)| false
• Search Google Scholar

O’Byrne, K. J., Gatzemeier, U., Bondarenko, I., et al.: Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol., 2011, 12, 795–805.

Bondarenko I. , 'Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study ' (2011 ) 12 Lancet Oncol. : 795 -805.

Bondarenko I.Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX studyLancet Oncol.201112795805)| false
• Search Google Scholar

Schwab, R., Pinter, F., Moldvay, J., et al.: Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. J. Clin. Oncol., 2005, 23, 7736–7738.

Moldvay J. , 'Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib ' (2005 ) 23 J. Clin. Oncol. : 7736 -7738.

Moldvay J.Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinibJ. Clin. Oncol.20052377367738)| false
• Search Google Scholar

Lynch, T. J., Bell, D. W., Sordella, R., et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350, 2129–2139.

Sordella R. , 'Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib ' (2004 ) 350 N. Engl. J. Med. : 2129 -2139.

Sordella R.Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN. Engl. J. Med.200435021292139)| false
• Search Google Scholar

Paez, J. G., Janne, P. A., Lee, J. C., et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304, 1497–1500.

Lee J. C. , 'EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy ' (2004 ) 304 Science : 1497 -1500.

Lee J. C.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430414971500)| false
• Search Google Scholar

Riely, G. J., Marks, J., Pao, W.: KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc., 2009, 6, 201–205.

Pao W. , 'KRAS mutations in non-small cell lung cancer ' (2009 ) 6 Proc. Am. Thorac. Soc. : 201 -205.

Pao W.KRAS mutations in non-small cell lung cancerProc. Am. Thorac. Soc.20096201205)| false
• Search Google Scholar

Shigematsu, H., Lin, L., Takahashi, T., et al.: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, 97, 339–346.

Takahashi T. , 'Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers ' (2005 ) 97 J. Natl. Cancer Inst. : 339 -346.

Takahashi T.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ. Natl. Cancer Inst.200597339346)| false
• Search Google Scholar

Pinter, F., Papay, J., Almasi, A., et al.: Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J. Mol. Diagn., 2008, 10, 160–168.

Almasi A. , 'Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry ' (2008 ) 10 J. Mol. Diagn. : 160 -168.

Almasi A.Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistryJ. Mol. Diagn.200810160168)| false
• Search Google Scholar

Cappuzzo, F., Jänne, P. A., Skokan, M., et al.: MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann. Oncol., 2009, 20, 298–304.

Skokan M. , 'MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients ' (2009 ) 20 Ann. Oncol. : 298 -304.

Skokan M.MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnn. Oncol.200920298304)| false
• Search Google Scholar

Becker, A., Crombag, L., Heideman, D. A. M., et al.: Retreatment with erlotinib. Regain of EGFR-TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer, 2011, 47, 2603–2606.

Heideman D. A. M. , 'Retreatment with erlotinib. Regain of EGFR-TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment ' (2011 ) 47 Eur. J. Cancer : 2603 -2606.

Heideman D. A. M.Retreatment with erlotinib. Regain of EGFR-TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatmentEur. J. Cancer20114726032606)| false
• Search Google Scholar

Watanabe, S., Tanaka, J., Ota, T.: Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer, 2011, 11, 1.

Ota T. , 'Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis ' (2011 ) 11 BMC Cancer : 1 -.

Ota T.Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysisBMC Cancer2011111)| false
• Search Google Scholar

Shaw, A. T., Yeap, B. Y., Solomon, B. J., et al.: Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol., 2011, 12, 1004–1012.

Solomon B. J. , 'Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis ' (2011 ) 12 Lancet Oncol. : 1004 -1012.

Solomon B. J.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol.20111210041012)| false
• Search Google Scholar